A dense, chemically inert noble metal with no known biological function — yet platinum compounds are the backbone of chemotherapy for ovarian, testicular, lung, and bladder cancers. The discovery that cisplatin inhibits bacterial cell division (Rosenberg, 1965) led to one of oncology's most important drug classes. What is only now emerging is that the gut microbiome profoundly influences whether platinum chemotherapy works or fails.
Cisplatin Mechanism
- Cisplatin (cis-diamminedichloroplatinum(II)) forms intrastrand DNA crosslinks, primarily at GG and AG sequences, blocking replication and triggering apoptosis.
- Second-generation carboplatin has reduced nephrotoxicity; third-generation oxaliplatin has a distinct spectrum of activity against colorectal cancer.
- All platinum compounds ultimately kill cells by inducing DNA damage beyond the cell's repair capacity.
Microbiome-Dependent Efficacy
The gut microbiome is not a bystander during chemotherapy — it is a determinant of response:
- Antibiotic-induced dysbiosis increases tumor growth AND platinum resistance — germ-free and antibiotic-treated mice show reduced cisplatin efficacy, demonstrating that intact gut microbiota are required for full chemotherapeutic effect.
- Immune surveillance dependency — The microbiome primes tumor-infiltrating immune cells (particularly CD8+ T cells) that are required for cisplatin to eliminate cancer stem cells. Without this immune component, platinum kills bulk tumor cells but spares resistant clones.
- Microbial metabolite modulation — Short-chain fatty acids (especially butyrate) from commensal bacteria enhance cisplatin-induced apoptosis in tumor cells through HDAC inhibition.
Ferroptosis Resistance
The primary mechanism of platinum resistance converges on ferroptosis evasion:
- Keap1-Nrf2-GPX4 axis — Platinum-resistant cells upregulate Nrf2, which activates GPX4 (glutathione peroxidase 4), the master suppressor of ferroptosis. This simultaneously blocks both cisplatin-induced apoptosis and ferroptosis.
- Glutathione (GSH) is the most altered pathway in platinum-resistant cells. Elevated GSH directly inactivates cisplatin (Pt-GSH conjugation) and fuels GPX4 to prevent lipid peroxidation.
- Iron homeostasis disruption — Resistant cells alter iron handling to minimize Fenton chemistry, reducing the oxidative stress that platinum compounds rely on for cytotoxicity.
Glutathione Connection
- Cisplatin resistance and glutathione metabolism are inseparable: GSH conjugation is the primary detoxification route, and gamma-glutamylcysteine synthetase upregulation is a hallmark of resistant clones.
- This creates a therapeutic paradox: interventions that deplete glutathione may resensitize tumors to platinum but also compromise host antioxidant defense.
- The microbiome influences systemic glutathione through cysteine and glycine metabolism, providing another mechanism for microbiome-dependent platinum sensitivity.
Clinical Significance
- Ovarian cancer: Platinum-based chemotherapy achieves ~80% initial response rate, but ~70% of patients develop resistance. The Keap1-Nrf2 pathway is now a major therapeutic target for resensitization.
- Colorectal cancer: Oxaliplatin efficacy correlates with pre-treatment microbiome composition, with higher Fusobacterium nucleatum abundance predicting poorer response.
- Nephrotoxicity: Cisplatin-induced kidney injury involves ferroptotic cell death in proximal tubule cells, linking platinum toxicity to the same ferroptosis pathway that governs resistance.
Cross-References
- iron — Ferroptosis substrate and resistance determinant
- glutathione — Primary detoxification pathway for cisplatin
- ferroptosis — The cell death pathway platinum compounds exploit
- breast cancer, ovarian cancer — Primary clinical applications